Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on May 21, 2012. The report addresses a regulatory notice regarding the company's continued listing status on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the Market Value of Listed Securities, which failed to meet the required threshold of $35 million for 30 consecutive business days.
Material Changes
The material change reported is the failure to comply with NASDAQ Listing Rule 5550(b)(2) due to insufficient market value. Consequently, the company received a formal notice of non-compliance from the Listing Qualifications staff of The NASDAQ Stock Market LLC.
Outlook, Risks, and Contingencies
- Compliance Period: NASDAQ has granted the company 180 calendar days (until November 19, 2012) to regain compliance.
- Regaining Compliance: The company must maintain a Market Value of Listed Securities of at least $35 million for a minimum of ten consecutive business days.
- Current Trading Status: The notice has no immediate effect on the listing or trading of the company's common stock.
- Risks: There is no assurance the company will regain compliance. Failure to do so by the deadline will result in a delisting notification, at which point the company may appeal to a Hearings Panel.
- Forward-Looking Statements: The report includes standard disclaimers that future results may differ materially from expectations due to various risks and uncertainties.
Investor Verification Checklist
- Verify the current market capitalization and stock price trends to assess the likelihood of meeting the $35 million threshold.
- Monitor the company's stock trading volume and price stability over the next 10 consecutive business days.
- Review the company's most recent Form 10-K for detailed financial health and risk factors not included in this 8-K.
- Watch for any subsequent filings regarding the company's appeal process if the compliance deadline is missed.